Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFLECT I: Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy in Pulmonary Lesions
NCT06809946Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
- Sponsor
- University Medical Center Groningen
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Conditions
- lung neoplasm
01
Overview
Phase 2, open-label trial of bevacizumab-IRDye800CW in lung neoplasm (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Fluorescent signal of malignant lesion versus non-tumorous tissue. Planned start Aug 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- Open-label
15 mg bevacizumab-800CW
Fluorescence molecular imaging during bronchoscopy with bevacizumab-800CW at dose of 15 mg
25 mg bevacizumab-800CW
Fluorescence molecular imaging during bronchoscopy with bevacizumab-800CW at dose of 25 mg
03
Who it enrols
Adults with at least one pulmonary nodule considered malignant, fit for bronchoscopy. Excludes pregnant/breastfeeding women and those with a history of infusion reactions to bevacizumab.
04
Endpoints
Primary
Fluorescent signal of malignant lesion versus non-tumorous tissue
Secondary
Fluorescence signal analyses
Optimal dose of bevacizumab-800CW
Safety of bevacizumab-800CW injection and fluorescence molecular imaging
Beyond the preview
Go deeper on NCT06809946.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809946.